Development of New Antivirals for Herpesviruses
The long-term treatment of herpesvirus infections with current antivirals in immunocompromised hosts leads to the development of drug-resistant viruses. Because nearly all currently available antivirals finally target viral DNA polymerase, virus resistant to one drug often shows cross-resistance to...
Gespeichert in:
| Veröffentlicht in: | Antiviral Chemistry and Chemotherapy 2003-12, Vol.14 (6), p.299-308 |
|---|---|
| 1. Verfasser: | |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 308 |
|---|---|
| container_issue | 6 |
| container_start_page | 299 |
| container_title | Antiviral Chemistry and Chemotherapy |
| container_volume | 14 |
| creator | Eizuru, Yoshito |
| description | The long-term treatment of herpesvirus infections with current antivirals in immunocompromised hosts leads to the development of drug-resistant viruses. Because nearly all currently available antivirals finally target viral DNA polymerase, virus resistant to one drug often shows cross-resistance to other drugs. In addition, nearly all the antivirals show various kinds of side effects or poor bioavailability. This evidence highlights the need for developing new antivirals for herpesviruses that have the different viral targets. Recently, high-throughput screening of large compound collections for inhibiting specific viral enzymes, or in vitro cell culture assay, has identified several new antivirals that target different viral proteins. These include the inhibitors of helicase/primase complex, terminase complex, portal protein and UL97 protein kinase. In addition, non-nucleoside inhibitors for viral DNA polymerase have been also developed. This review will focus on these new compounds that directly inhibit viral replication. |
| doi_str_mv | 10.1177/095632020301400602 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_71539794</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sage_id>10.1177_095632020301400602</sage_id><sourcerecordid>2342379051</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3872-bdf18d141d0da41854d21b7e775299cb236b570f3b9f5cd1bdfa2efc8f5ede513</originalsourceid><addsrcrecordid>eNqFkE1Lw0AQhhdRbK3-AQ8SEL3VzuxHNnss9ROKXvQcNsmspKRJ3W0q_ntTW6go6GmGmWfmnXkZO0W4QtR6BEbFggMHASgBYuB7rM9BwpBDHO9_y3vsKIQZgEiUMIesh9LEiRFxn42uaUVVs5hTvYwaFz3SezSul-Wq9LYKkWt8dE9-QaErtIHCMTtwXYNOtnHAXm5vnif3w-nT3cNkPB3mItF8mBUOkwIlFlBYiYmSBcdMk9aKG5NnXMSZ0uBEZpzKC-x4y8nliVNUkEIxYJebvQvfvLUUlum8DDlVla2paUOqsftEG_kviAkg18J04PkPcNa0vu6eSLmQXGgDX7p8Q-W-CcGTSxe-nFv_kSKka9fT3653Q2fb1W02p2I3srW5Ay62gA25rZy3dV6GHackxsKs1UcbLthX2t33h_QnRhGU0A</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2342379051</pqid></control><display><type>article</type><title>Development of New Antivirals for Herpesviruses</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>Eizuru, Yoshito</creator><creatorcontrib>Eizuru, Yoshito</creatorcontrib><description>The long-term treatment of herpesvirus infections with current antivirals in immunocompromised hosts leads to the development of drug-resistant viruses. Because nearly all currently available antivirals finally target viral DNA polymerase, virus resistant to one drug often shows cross-resistance to other drugs. In addition, nearly all the antivirals show various kinds of side effects or poor bioavailability. This evidence highlights the need for developing new antivirals for herpesviruses that have the different viral targets. Recently, high-throughput screening of large compound collections for inhibiting specific viral enzymes, or in vitro cell culture assay, has identified several new antivirals that target different viral proteins. These include the inhibitors of helicase/primase complex, terminase complex, portal protein and UL97 protein kinase. In addition, non-nucleoside inhibitors for viral DNA polymerase have been also developed. This review will focus on these new compounds that directly inhibit viral replication.</description><identifier>ISSN: 2040-2066</identifier><identifier>ISSN: 0956-3202</identifier><identifier>EISSN: 2040-2066</identifier><identifier>DOI: 10.1177/095632020301400602</identifier><identifier>PMID: 14968936</identifier><language>eng</language><publisher>London, England: SAGE Publications</publisher><subject>Antibiotics. Antiinfectious agents. Antiparasitic agents ; Antiviral agents ; Antiviral Agents - pharmacology ; Antiviral drugs ; Bioavailability ; Biological and medical sciences ; Cell culture ; Cross-resistance ; Deoxyribonucleic acid ; Disease resistance ; DNA ; DNA helicase ; DNA polymerase ; DNA Replication - drug effects ; DNA, Viral - biosynthesis ; DNA, Viral - drug effects ; DNA-directed DNA polymerase ; Drug resistance ; Enzyme Inhibitors - pharmacology ; Ganciclovir kinase ; Herpesviridae - drug effects ; Herpesviridae - genetics ; Herpesvirus ; High-throughput screening ; Immunocompromised hosts ; Kinases ; Medical sciences ; Pharmacology. Drug treatments ; Phosphotransferases (Alcohol Group Acceptor) - antagonists & inhibitors ; Portal protein ; Primase ; Protein kinase ; Terminase</subject><ispartof>Antiviral Chemistry and Chemotherapy, 2003-12, Vol.14 (6), p.299-308</ispartof><rights>2003 SAGE Publications</rights><rights>2004 INIST-CNRS</rights><rights>2003 SAGE Publications. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the associated terms available at: https://uk.sagepub.com/en-gb/eur/reusing-open-access-and-sage-choice-content</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3872-bdf18d141d0da41854d21b7e775299cb236b570f3b9f5cd1bdfa2efc8f5ede513</citedby><cites>FETCH-LOGICAL-c3872-bdf18d141d0da41854d21b7e775299cb236b570f3b9f5cd1bdfa2efc8f5ede513</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>313,314,776,780,788,27901,27903,27904</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=15416391$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/14968936$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Eizuru, Yoshito</creatorcontrib><title>Development of New Antivirals for Herpesviruses</title><title>Antiviral Chemistry and Chemotherapy</title><addtitle>Antivir Chem Chemother</addtitle><description>The long-term treatment of herpesvirus infections with current antivirals in immunocompromised hosts leads to the development of drug-resistant viruses. Because nearly all currently available antivirals finally target viral DNA polymerase, virus resistant to one drug often shows cross-resistance to other drugs. In addition, nearly all the antivirals show various kinds of side effects or poor bioavailability. This evidence highlights the need for developing new antivirals for herpesviruses that have the different viral targets. Recently, high-throughput screening of large compound collections for inhibiting specific viral enzymes, or in vitro cell culture assay, has identified several new antivirals that target different viral proteins. These include the inhibitors of helicase/primase complex, terminase complex, portal protein and UL97 protein kinase. In addition, non-nucleoside inhibitors for viral DNA polymerase have been also developed. This review will focus on these new compounds that directly inhibit viral replication.</description><subject>Antibiotics. Antiinfectious agents. Antiparasitic agents</subject><subject>Antiviral agents</subject><subject>Antiviral Agents - pharmacology</subject><subject>Antiviral drugs</subject><subject>Bioavailability</subject><subject>Biological and medical sciences</subject><subject>Cell culture</subject><subject>Cross-resistance</subject><subject>Deoxyribonucleic acid</subject><subject>Disease resistance</subject><subject>DNA</subject><subject>DNA helicase</subject><subject>DNA polymerase</subject><subject>DNA Replication - drug effects</subject><subject>DNA, Viral - biosynthesis</subject><subject>DNA, Viral - drug effects</subject><subject>DNA-directed DNA polymerase</subject><subject>Drug resistance</subject><subject>Enzyme Inhibitors - pharmacology</subject><subject>Ganciclovir kinase</subject><subject>Herpesviridae - drug effects</subject><subject>Herpesviridae - genetics</subject><subject>Herpesvirus</subject><subject>High-throughput screening</subject><subject>Immunocompromised hosts</subject><subject>Kinases</subject><subject>Medical sciences</subject><subject>Pharmacology. Drug treatments</subject><subject>Phosphotransferases (Alcohol Group Acceptor) - antagonists & inhibitors</subject><subject>Portal protein</subject><subject>Primase</subject><subject>Protein kinase</subject><subject>Terminase</subject><issn>2040-2066</issn><issn>0956-3202</issn><issn>2040-2066</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2003</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNqFkE1Lw0AQhhdRbK3-AQ8SEL3VzuxHNnss9ROKXvQcNsmspKRJ3W0q_ntTW6go6GmGmWfmnXkZO0W4QtR6BEbFggMHASgBYuB7rM9BwpBDHO9_y3vsKIQZgEiUMIesh9LEiRFxn42uaUVVs5hTvYwaFz3SezSul-Wq9LYKkWt8dE9-QaErtIHCMTtwXYNOtnHAXm5vnif3w-nT3cNkPB3mItF8mBUOkwIlFlBYiYmSBcdMk9aKG5NnXMSZ0uBEZpzKC-x4y8nliVNUkEIxYJebvQvfvLUUlum8DDlVla2paUOqsftEG_kviAkg18J04PkPcNa0vu6eSLmQXGgDX7p8Q-W-CcGTSxe-nFv_kSKka9fT3653Q2fb1W02p2I3srW5Ay62gA25rZy3dV6GHackxsKs1UcbLthX2t33h_QnRhGU0A</recordid><startdate>200312</startdate><enddate>200312</enddate><creator>Eizuru, Yoshito</creator><general>SAGE Publications</general><general>International Medical Press</general><general>Sage Publications Ltd</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7QR</scope><scope>7T5</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FD</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>P64</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7U9</scope><scope>7X8</scope></search><sort><creationdate>200312</creationdate><title>Development of New Antivirals for Herpesviruses</title><author>Eizuru, Yoshito</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3872-bdf18d141d0da41854d21b7e775299cb236b570f3b9f5cd1bdfa2efc8f5ede513</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2003</creationdate><topic>Antibiotics. Antiinfectious agents. Antiparasitic agents</topic><topic>Antiviral agents</topic><topic>Antiviral Agents - pharmacology</topic><topic>Antiviral drugs</topic><topic>Bioavailability</topic><topic>Biological and medical sciences</topic><topic>Cell culture</topic><topic>Cross-resistance</topic><topic>Deoxyribonucleic acid</topic><topic>Disease resistance</topic><topic>DNA</topic><topic>DNA helicase</topic><topic>DNA polymerase</topic><topic>DNA Replication - drug effects</topic><topic>DNA, Viral - biosynthesis</topic><topic>DNA, Viral - drug effects</topic><topic>DNA-directed DNA polymerase</topic><topic>Drug resistance</topic><topic>Enzyme Inhibitors - pharmacology</topic><topic>Ganciclovir kinase</topic><topic>Herpesviridae - drug effects</topic><topic>Herpesviridae - genetics</topic><topic>Herpesvirus</topic><topic>High-throughput screening</topic><topic>Immunocompromised hosts</topic><topic>Kinases</topic><topic>Medical sciences</topic><topic>Pharmacology. Drug treatments</topic><topic>Phosphotransferases (Alcohol Group Acceptor) - antagonists & inhibitors</topic><topic>Portal protein</topic><topic>Primase</topic><topic>Protein kinase</topic><topic>Terminase</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Eizuru, Yoshito</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Chemoreception Abstracts</collection><collection>Immunology Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Virology and AIDS Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Antiviral Chemistry and Chemotherapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Eizuru, Yoshito</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Development of New Antivirals for Herpesviruses</atitle><jtitle>Antiviral Chemistry and Chemotherapy</jtitle><addtitle>Antivir Chem Chemother</addtitle><date>2003-12</date><risdate>2003</risdate><volume>14</volume><issue>6</issue><spage>299</spage><epage>308</epage><pages>299-308</pages><issn>2040-2066</issn><issn>0956-3202</issn><eissn>2040-2066</eissn><abstract>The long-term treatment of herpesvirus infections with current antivirals in immunocompromised hosts leads to the development of drug-resistant viruses. Because nearly all currently available antivirals finally target viral DNA polymerase, virus resistant to one drug often shows cross-resistance to other drugs. In addition, nearly all the antivirals show various kinds of side effects or poor bioavailability. This evidence highlights the need for developing new antivirals for herpesviruses that have the different viral targets. Recently, high-throughput screening of large compound collections for inhibiting specific viral enzymes, or in vitro cell culture assay, has identified several new antivirals that target different viral proteins. These include the inhibitors of helicase/primase complex, terminase complex, portal protein and UL97 protein kinase. In addition, non-nucleoside inhibitors for viral DNA polymerase have been also developed. This review will focus on these new compounds that directly inhibit viral replication.</abstract><cop>London, England</cop><pub>SAGE Publications</pub><pmid>14968936</pmid><doi>10.1177/095632020301400602</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2040-2066 |
| ispartof | Antiviral Chemistry and Chemotherapy, 2003-12, Vol.14 (6), p.299-308 |
| issn | 2040-2066 0956-3202 2040-2066 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_71539794 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection |
| subjects | Antibiotics. Antiinfectious agents. Antiparasitic agents Antiviral agents Antiviral Agents - pharmacology Antiviral drugs Bioavailability Biological and medical sciences Cell culture Cross-resistance Deoxyribonucleic acid Disease resistance DNA DNA helicase DNA polymerase DNA Replication - drug effects DNA, Viral - biosynthesis DNA, Viral - drug effects DNA-directed DNA polymerase Drug resistance Enzyme Inhibitors - pharmacology Ganciclovir kinase Herpesviridae - drug effects Herpesviridae - genetics Herpesvirus High-throughput screening Immunocompromised hosts Kinases Medical sciences Pharmacology. Drug treatments Phosphotransferases (Alcohol Group Acceptor) - antagonists & inhibitors Portal protein Primase Protein kinase Terminase |
| title | Development of New Antivirals for Herpesviruses |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-23T08%3A15%3A39IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Development%20of%20New%20Antivirals%20for%20Herpesviruses&rft.jtitle=Antiviral%20Chemistry%20and%20Chemotherapy&rft.au=Eizuru,%20Yoshito&rft.date=2003-12&rft.volume=14&rft.issue=6&rft.spage=299&rft.epage=308&rft.pages=299-308&rft.issn=2040-2066&rft.eissn=2040-2066&rft_id=info:doi/10.1177/095632020301400602&rft_dat=%3Cproquest_cross%3E2342379051%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2342379051&rft_id=info:pmid/14968936&rft_sage_id=10.1177_095632020301400602&rfr_iscdi=true |